Non-statin medications for lowering cholesterol
Pro Research Analysisby 
Searched over 200M research papers
Non-Statin Cholesterol-Lowering Medications: Key Options and Mechanisms
Several non-statin medications are available for lowering cholesterol, especially for patients who cannot tolerate statins or need additional LDL cholesterol reduction. The main non-statin options include ezetimibe, PCSK9 inhibitors, bempedoic acid, bile acid sequestrants, fibrates, niacin, and newer agents like inclisiran and evinacumab 126.
Ezetimibe for LDL Cholesterol Reduction
Ezetimibe works by blocking cholesterol absorption in the intestine. It is commonly used as a second-line therapy, either alone or in combination with statins, and has shown cardiovascular benefits, especially after acute coronary syndrome 157. Ezetimibe is also used in children and adolescents with familial hypercholesterolemia .
PCSK9 Inhibitors: Potent LDL Lowering
PCSK9 inhibitors, such as evolocumab and alirocumab, are injectable monoclonal antibodies that significantly lower LDL cholesterol by increasing the liver’s ability to remove LDL from the blood. These agents are among the most effective non-statin therapies and are recommended for patients at high cardiovascular risk who do not reach LDL targets with statins and ezetimibe 1356+2 MORE. PCSK9 inhibitors are also approved for use in children with certain genetic cholesterol disorders .
Bempedoic Acid: An Oral Alternative
Bempedoic acid is an oral medication that inhibits cholesterol synthesis in the liver through a pathway similar to statins but is not associated with muscle-related side effects. It is a valuable option for statin-intolerant patients and can be used alone or with ezetimibe 1236.
Bile Acid Sequestrants and Fibrates
Bile acid sequestrants (such as colesevelam) bind bile acids in the intestine, leading to increased cholesterol breakdown. They are considered optional secondary agents, especially for patients intolerant to ezetimibe 245. Fibrates primarily lower triglycerides and have a modest effect on LDL cholesterol; they are sometimes used in combination with other agents 28.
New and Emerging Therapies
Inclisiran is a small interfering RNA that reduces PCSK9 production, offering similar LDL-lowering effects as PCSK9 monoclonal antibodies 16. Evinacumab, an ANGPTL3 inhibitor, is approved for patients with refractory hypercholesterolemia, including children with severe genetic forms 46. Other novel therapies in development include antisense oligonucleotides and gene-based treatments targeting specific lipid pathways 26.
Efficacy and Safety of Non-Statin Therapies
Non-statin agents, especially PCSK9 inhibitors and ezetimibe, have demonstrated significant reductions in LDL cholesterol and cardiovascular events, both as monotherapy and when added to statins 1356+2 MORE. Bempedoic acid and inclisiran also show promising results in clinical trials 1236. Alternative strategies, such as combining moderate-intensity statins with ezetimibe, provide similar cardiovascular protection as high-intensity statins, with fewer side effects like new-onset diabetes and drug intolerance .
Special Considerations in Children and Adolescents
For young patients with familial hypercholesterolemia, ezetimibe, PCSK9 inhibitors, and evinacumab are approved and effective adjuncts to lifestyle changes and statin therapy .
Conclusion
Non-statin cholesterol-lowering medications offer effective alternatives or additions to statin therapy, especially for patients who are statin-intolerant or require further LDL reduction. Ezetimibe and PCSK9 inhibitors are the most established options, while bempedoic acid, inclisiran, and other novel agents expand the therapeutic landscape. These medications help more patients achieve cholesterol goals and reduce cardiovascular risk 1234+5 MORE.
Sources and full results
Most relevant research papers on this topic